Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 11:28AM ET
1.04
Dollar change
+0.01
Percentage change
0.96
%
Index- P/E- EPS (ttm)-0.31 Insider Own6.50% Shs Outstand74.42M Perf Week0.96%
Market Cap78.43M Forward P/E- EPS next Y-0.28 Insider Trans0.00% Shs Float70.52M Perf Month1.95%
Income-20.60M PEG- EPS next Q-0.08 Inst Own6.97% Short Float1.48% Perf Quarter-14.41%
Sales0.00M P/S- EPS this Y-10.25% Inst Trans31.31% Short Ratio2.54 Perf Half Y-53.37%
Book/sh0.28 P/B3.70 EPS next Y17.15% ROA-72.28% Short Interest1.04M Perf Year-14.06%
Cash/sh0.35 P/C2.96 EPS next 5Y- ROE-101.82% 52W Range0.88 - 3.39 Perf YTD-22.97%
Dividend Est.- P/FCF- EPS past 5Y18.01% ROI-97.52% 52W High-69.36% Beta1.92
Dividend TTM- Quick Ratio9.01 Sales past 5Y0.00% Gross Margin- 52W Low17.77% ATR (14)0.06
Dividend Ex-Date- Current Ratio9.01 EPS Y/Y TTM6.08% Oper. Margin0.00% RSI (14)49.20 Volatility2.40% 6.92%
Employees29 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price5.49
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q62.89% Payout- Rel Volume0.84 Prev Close1.03
Sales Surprise- EPS Surprise65.52% Sales Q/Q- EarningsMar 07 AMC Avg Volume411.02K Price1.04
SMA200.53% SMA50-4.39% SMA200-40.79% Trades Volume120,967 Change0.96%
Date Action Analyst Rating Change Price Target Change
Oct-06-22Initiated Maxim Group Buy $3
Feb-17-21Initiated H.C. Wainwright Buy $15
Mar-14-24 08:45AM
Mar-10-24 08:36AM
Mar-07-24 09:55PM
04:01PM
Mar-06-24 08:00AM
08:30AM Loading…
Mar-05-24 08:30AM
07:00AM
Mar-04-24 07:00AM
Feb-28-24 07:00AM
Feb-15-24 08:00AM
Feb-14-24 08:30AM
07:00AM
Feb-07-24 08:55AM
Jan-09-24 10:25AM
07:00AM
07:00AM Loading…
Jan-04-24 07:00AM
Dec-07-23 07:00AM
Nov-29-23 10:45AM
Nov-09-23 08:45AM
07:00AM
06:30AM
Nov-05-23 02:29PM
Nov-03-23 12:03PM
07:00AM
Oct-23-23 09:50AM
08:45AM
07:05AM
07:00AM
Oct-20-23 10:31AM
07:00AM
07:00AM Loading…
Oct-16-23 07:00AM
Oct-13-23 09:00AM
Oct-11-23 09:00AM
Sep-26-23 08:00AM
Sep-19-23 07:00AM
Sep-07-23 09:22AM
Sep-06-23 07:00AM
Aug-21-23 07:00AM
Aug-17-23 09:35AM
Aug-14-23 07:00AM
Aug-08-23 08:50AM
Aug-04-23 07:05AM
07:00AM
Jul-31-23 06:55AM
Jun-22-23 07:00AM
Jun-05-23 07:00AM
May-26-23 11:30AM
May-25-23 05:41PM
May-24-23 10:26AM
May-10-23 07:00AM
May-07-23 01:18PM
May-05-23 07:00AM
Apr-26-23 10:44AM
Apr-12-23 07:23AM
07:00AM
06:45AM
Mar-28-23 07:00AM
Mar-27-23 11:57AM
Mar-06-23 09:48AM
Mar-03-23 07:00AM
Feb-21-23 07:00AM
Dec-16-22 09:40AM
Dec-08-22 08:45AM
Dec-05-22 12:00PM
Dec-02-22 10:59AM
09:15AM
Dec-01-22 07:32AM
Nov-29-22 09:40AM
Nov-21-22 09:01AM
Nov-18-22 09:55AM
Nov-10-22 09:01AM
Nov-07-22 08:03AM
08:01AM
Oct-27-22 07:00AM
Oct-18-22 10:46AM
Sep-07-22 07:00AM
Aug-11-22 07:00AM
Jul-27-22 07:00AM
Jul-11-22 06:19AM
Jun-28-22 07:00AM
Jun-17-22 07:00AM
Jun-01-22 12:21PM
May-11-22 10:19AM
May-10-22 07:00AM
May-05-22 04:01PM
May-04-22 07:00AM
May-02-22 07:00AM
Apr-28-22 07:00AM
Apr-21-22 07:00AM
Apr-14-22 07:00AM
Apr-12-22 07:00AM
Apr-08-22 01:05PM
01:03PM
Apr-06-22 07:00AM
Mar-31-22 07:00AM
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.